PL2978419T3 - Kompozycje do zwiększania żywotności komórek i metody ich stosowania - Google Patents
Kompozycje do zwiększania żywotności komórek i metody ich stosowaniaInfo
- Publication number
- PL2978419T3 PL2978419T3 PL14775675T PL14775675T PL2978419T3 PL 2978419 T3 PL2978419 T3 PL 2978419T3 PL 14775675 T PL14775675 T PL 14775675T PL 14775675 T PL14775675 T PL 14775675T PL 2978419 T3 PL2978419 T3 PL 2978419T3
- Authority
- PL
- Poland
- Prior art keywords
- vitability
- compositions
- cells
- increasing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361804690P | 2013-03-24 | 2013-03-24 | |
| US14/140,083 US9872865B2 (en) | 2013-03-24 | 2013-12-24 | Compositions for improving cell viability and methods of use thereof |
| PCT/US2014/018040 WO2014158547A1 (en) | 2013-03-24 | 2014-02-24 | Compositions for improving cell viability and methods of use thereof |
| EP14775675.3A EP2978419B1 (en) | 2013-03-24 | 2014-02-24 | Compositions for improving cell viability and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2978419T3 true PL2978419T3 (pl) | 2020-10-19 |
Family
ID=51569584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14775675T PL2978419T3 (pl) | 2013-03-24 | 2014-02-24 | Kompozycje do zwiększania żywotności komórek i metody ich stosowania |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9872865B2 (pl) |
| EP (3) | EP4509120A3 (pl) |
| JP (6) | JP6495237B2 (pl) |
| KR (6) | KR102460746B1 (pl) |
| CN (3) | CN110787169B (pl) |
| AU (5) | AU2014242123B2 (pl) |
| CA (1) | CA2908683A1 (pl) |
| CY (1) | CY1123092T1 (pl) |
| DK (1) | DK2978419T3 (pl) |
| ES (1) | ES2796250T3 (pl) |
| HR (1) | HRP20200990T1 (pl) |
| HU (1) | HUE051105T2 (pl) |
| LT (1) | LT2978419T (pl) |
| ME (1) | ME03747B (pl) |
| PL (1) | PL2978419T3 (pl) |
| PT (1) | PT2978419T (pl) |
| RS (1) | RS60596B1 (pl) |
| SI (1) | SI2978419T1 (pl) |
| SM (1) | SMT202000326T1 (pl) |
| WO (1) | WO2014158547A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| BR112017026739A2 (pt) * | 2015-06-15 | 2018-08-28 | Nmd Pharma Aps | compostos para uso no tratamento de distúrbios neuromusculares |
| KR101743960B1 (ko) * | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
| EP3702470A3 (en) * | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| KR20190072521A (ko) * | 2016-09-12 | 2019-06-25 | 스티븐 호프만 | 치매를 치료하기 위한 조성물 |
| WO2018157014A1 (en) * | 2017-02-24 | 2018-08-30 | Duke University | Metabolic biomarkers for the identification and characterization of alzheimer's disease |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| EP3900714A4 (en) * | 2018-12-18 | 2022-09-21 | Santen Pharmaceutical Co., Ltd. | AGENT CONTAINING 4-PHENYLBUTYRATE, FOR THE PREVENTION OR TREATMENT OF PRESBYOPIA |
| BR112021022784A2 (pt) | 2019-05-14 | 2022-03-22 | Tyme Inc | Composições e métodos para tratamento do câncer |
| BR112022011951A2 (pt) | 2019-12-16 | 2022-09-06 | Amylyx Pharmaceuticals Inc | Tratamento de esclerose lateral amiotrófica e distúrbios relacionados |
| US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| IL295562A (en) * | 2020-02-13 | 2022-10-01 | Prilenia Neurotherapeutics Ltd | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| WO2022188029A1 (zh) * | 2021-03-09 | 2022-09-15 | 兆科药业（广州）有限公司 | 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物 |
| WO2022191296A1 (ja) * | 2021-03-10 | 2022-09-15 | 昭和電工マテリアルズ株式会社 | 培地組成物、細胞培養物の製造方法、及び細胞懸濁物 |
| CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
| CN113349300A (zh) * | 2021-06-07 | 2021-09-07 | 湖南农业大学 | 4-苯基丁酸在制备猪肠道保健产品中的应用 |
| IL312585A (en) * | 2021-11-08 | 2024-07-01 | Amylyx Pharmaceuticals Inc | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases |
| CN116159068A (zh) * | 2021-11-25 | 2023-05-26 | 香港理工大学深圳研究院 | 胆汁酸和/或胆汁酸受体激动剂的新应用 |
| US20230190709A1 (en) * | 2021-12-02 | 2023-06-22 | MarvelBiome, Inc. | Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions |
| US20230277630A1 (en) | 2022-03-02 | 2023-09-07 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| US12138272B2 (en) | 2022-05-12 | 2024-11-12 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| US20230372263A1 (en) | 2022-05-17 | 2023-11-23 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| WO2024015286A1 (en) * | 2022-07-11 | 2024-01-18 | AI Therapeutics, Inc. | Apilimod combination therapy |
| WO2024015281A1 (en) * | 2022-07-11 | 2024-01-18 | AI Therapeutics, Inc. | Apilimod combination therapy |
| WO2024054412A1 (en) | 2022-09-07 | 2024-03-14 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| WO2024072778A1 (en) | 2022-09-29 | 2024-04-04 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| WO2024095118A1 (en) | 2022-10-31 | 2024-05-10 | Novartis Ag | Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis |
| WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
| EP4649317A2 (en) * | 2023-01-12 | 2025-11-19 | Population Bio, Inc. | Methods and compositions for screening and treating alzheimer's disease |
| WO2025054193A2 (en) * | 2023-09-05 | 2025-03-13 | Amylyx Pharmaceuticals, Inc. | Compositions and methods for treating subjects with renal impairment |
| CN121197183A (zh) * | 2025-12-01 | 2025-12-26 | 中国农业科学院饲料研究所 | 3-oxoLCA在降低妊娠母体及其子代的氧化应激和炎症中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| WO2004096123A2 (en) | 2003-04-02 | 2004-11-11 | Regents Of The University Of Minnesota | Methods of promoting cell viability |
| CN101048164B (zh) | 2004-11-01 | 2012-05-09 | 柳署弘 | 降低肌萎缩性侧索硬化中神经变性的组合物 |
| WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| KR20080012258A (ko) | 2005-02-10 | 2008-02-11 | 리전츠 오브 더 유니버스티 오브 미네소타 | 시각장애를 치료하는 방법 |
| US20090312297A1 (en) | 2006-03-22 | 2009-12-17 | President And Fellows Of Harvard College | Methods for treating hypercholesterolemia and atherosclerosis |
| US7737175B2 (en) | 2007-06-01 | 2010-06-15 | Duke University | Methods and compositions for regulating HDAC4 activity |
| CA2649740A1 (en) * | 2008-01-14 | 2009-07-14 | Queen's University At Kingston | Therapies for cognition and learning enhancement |
| ES2332687B1 (es) | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| CA2723833A1 (en) | 2008-05-12 | 2009-11-19 | Umut Ozcan | Methods and compositions for the treatment of obesity |
| US20110142799A1 (en) | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| US20120157419A1 (en) | 2009-02-02 | 2012-06-21 | Tuvia Gilat | Methods and compositions for treating alzheimer's disease |
| EP2422787A1 (en) | 2010-08-17 | 2012-02-29 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
| US9632075B2 (en) | 2011-11-01 | 2017-04-25 | Meselex, Inc. | Prevention or attenuation of neuropathic pain by bile acids |
| EP2599477A1 (en) | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| US20150072967A1 (en) | 2012-03-20 | 2015-03-12 | Metselex, Inc. | Tauroursodeoxycholic acid attentuates or abolishes formation and deposition of amyloid-b peptide |
| US9872865B2 (en) * | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| EP3016654B2 (en) | 2013-07-01 | 2025-11-12 | Bruschettini S.r.l. | Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders |
| US10142799B2 (en) | 2014-08-19 | 2018-11-27 | Qualcomm Incorporated | Multicasting traffic using multi-connectivity |
-
2013
- 2013-12-24 US US14/140,083 patent/US9872865B2/en active Active
-
2014
- 2014-02-24 WO PCT/US2014/018040 patent/WO2014158547A1/en not_active Ceased
- 2014-02-24 DK DK14775675.3T patent/DK2978419T3/da active
- 2014-02-24 PT PT147756753T patent/PT2978419T/pt unknown
- 2014-02-24 CN CN201911065687.6A patent/CN110787169B/zh active Active
- 2014-02-24 JP JP2016505464A patent/JP6495237B2/ja active Active
- 2014-02-24 SI SI201431557T patent/SI2978419T1/sl unknown
- 2014-02-24 KR KR1020227015333A patent/KR102460746B1/ko active Active
- 2014-02-24 CN CN201480017771.XA patent/CN105050593B/zh active Active
- 2014-02-24 KR KR1020157030684A patent/KR102223250B1/ko active Active
- 2014-02-24 RS RS20200676A patent/RS60596B1/sr unknown
- 2014-02-24 CA CA2908683A patent/CA2908683A1/en active Pending
- 2014-02-24 HU HUE14775675A patent/HUE051105T2/hu unknown
- 2014-02-24 AU AU2014242123A patent/AU2014242123B2/en active Active
- 2014-02-24 ES ES14775675T patent/ES2796250T3/es active Active
- 2014-02-24 ME MEP-2020-117A patent/ME03747B/me unknown
- 2014-02-24 CN CN201910114290.5A patent/CN109999043B/zh active Active
- 2014-02-24 KR KR1020217041070A patent/KR102396714B1/ko active Active
- 2014-02-24 KR KR1020237040555A patent/KR102804813B1/ko active Active
- 2014-02-24 PL PL14775675T patent/PL2978419T3/pl unknown
- 2014-02-24 KR KR1020217005747A patent/KR20210025134A/ko not_active Ceased
- 2014-02-24 KR KR1020227037260A patent/KR102607635B1/ko active Active
- 2014-02-24 EP EP24200582.5A patent/EP4509120A3/en active Pending
- 2014-02-24 SM SM20200326T patent/SMT202000326T1/it unknown
- 2014-02-24 EP EP20169399.1A patent/EP3750531B1/en active Active
- 2014-02-24 EP EP14775675.3A patent/EP2978419B1/en active Active
- 2014-02-24 LT LTEP14775675.3T patent/LT2978419T/lt unknown
- 2014-02-24 HR HRP20200990TT patent/HRP20200990T1/hr unknown
-
2017
- 2017-12-11 US US15/837,866 patent/US10251896B2/en active Active
-
2019
- 2019-01-31 AU AU2019200658A patent/AU2019200658B2/en active Active
- 2019-02-20 US US16/280,861 patent/US11071742B2/en active Active
- 2019-03-06 JP JP2019040563A patent/JP6766198B2/ja active Active
-
2020
- 2020-02-04 US US16/781,239 patent/US10857162B2/en active Active
- 2020-04-02 US US16/838,975 patent/US20200230156A1/en not_active Abandoned
- 2020-06-30 CY CY20201100604T patent/CY1123092T1/el unknown
- 2020-09-16 JP JP2020155505A patent/JP7080944B2/ja active Active
-
2021
- 2021-03-22 AU AU2021201770A patent/AU2021201770B2/en active Active
- 2021-11-02 US US17/516,845 patent/US12186330B2/en active Active
- 2021-12-21 US US17/557,606 patent/US20220110948A1/en not_active Abandoned
-
2022
- 2022-05-25 JP JP2022085433A patent/JP7242945B2/ja active Active
- 2022-08-23 AU AU2022221410A patent/AU2022221410B2/en not_active Expired - Fee Related
-
2023
- 2023-03-08 JP JP2023035423A patent/JP7596421B2/ja active Active
-
2024
- 2024-11-19 US US18/952,187 patent/US20250275985A1/en active Pending
- 2024-11-27 JP JP2024206282A patent/JP7806187B2/ja active Active
-
2025
- 2025-03-11 AU AU2025201758A patent/AU2025201758A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2978419T3 (pl) | Kompozycje do zwiększania żywotności komórek i metody ich stosowania | |
| IL282202A (en) | Compositions and methods for personalized neoplasia vaccines | |
| IL241112B (en) | Methods and compositions for modification of hla | |
| EP2953474A4 (en) | COMPOSITIONS AND METHODS | |
| IL245573B (en) | Cell | |
| ME03557B (me) | Privremena zaštiтa normalnih ćelija током hemoterapije | |
| PL2970974T3 (pl) | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania | |
| HRP20180817T1 (hr) | Sastavi i postupci za modulaciju farnesoid-x-receptora | |
| IL265876A (en) | Preparations that include 15-ohepa and methods of using them | |
| PL2981822T3 (pl) | Kompozycje i sposoby modulacji czynnika wzrostu | |
| HRP20170840T1 (hr) | Supstituirani ksantini i metode njihove uporabe | |
| SG10201708595YA (en) | Cenicriviroc compositions and methods of making and using the same | |
| EP2943591A4 (en) | METHOD AND COMPOSITIONS FOR PROFILING SINGLE CELL EXPRESSION | |
| PL2830654T3 (pl) | Sposoby i kompozycje do leczenia zapalenia | |
| PL3030519T3 (pl) | Trójpierścieniowe związki benzoksaborolu i ich zastosowania | |
| EP2970569A4 (en) | PERSISTENT CARBENE AND COMPOSITIONS WITH IT | |
| DK2956410T3 (da) | Kompositsilicium- eller komposittinpartikler | |
| GB201322456D0 (en) | Radiotracer compositions and methods | |
| PL3613423T3 (pl) | Kompozycje hialuronanu o dużej sprężystości i ich zastosowanie | |
| IL245272B (en) | pif-transfected cells and methods of use | |
| PL2968346T3 (pl) | Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego | |
| PL3055307T3 (pl) | Podstawione berbiny i ich synteza | |
| SMT202000473T1 (it) | Composizione comprendente idrocortisone | |
| DK3068428T3 (da) | Annexin-ii-variant-sammensætninger og fremgangsmåder | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation |